Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients

Inclusion Criteria

• •Age ≥ 18 years Histologically or cytologically confirmed advanced malignancy (including but not limited to urothelial carcinoma) eligible for MMAE-containing ADC therapy (e.g., EV, DV, BV)
• •ECOG performance status 0-2
• •No baseline peripheral neuropathy ≥ Grade 1 (CTCAE v5.0)
• •Stable tumor status without other neurotoxic drugs in the past 2 months
• •Adequate organ function (blood counts, liver and kidney function) per protocol
• •Expected survival ≥ 3 months
• •Ability and willingness to comply with study procedures and provide written informed consent
• •Renal failure requiring dialysis
• •Immunodeficiency or history of organ transplantation
• •Severe nausea, headache, fatigue, or other debilitating symptoms
• •Active tuberculosis or uncontrolled pleural/pericardial effusion/ascites
• •Hypersensitivity to monoclonal antibodies or study device components
• •Participation in other clinical trials within 4 weeks
• •Known bleeding or coagulation disorders or receiving thrombolytic therapy
• •Any other condition judged by the investigator to preclude safe participation